Completed PHASE2 INTERVENTIONAL 1-arm
NCT00496873
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
A Single-Center, Open-Label Study to Evaluate the Safety and Efficacy of Nipent, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated and Treated, Stage III or IV, Low-Grade B-Cell Non-Hodgkin's Lymphoma or Bulky Lymphoma
Sponsor: Astex Pharmaceuticals, Inc.
Conditions
Lymphoma
Updated 1 time since 2024 Last updated: Mar 27, 2023 Started: Jun 30, 2005 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Lymphoma, this trial is completed. The trial is conducted by Astex Pharmaceuticals, Inc. and has accumulated 1 data snapshot since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Completed — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Astex Pharmaceuticals, Inc.
- M.D. Anderson Cancer Center
- Pharmatech
Data source: M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .